Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 26, 2017 - Issue 2
Submit an article Journal homepage
858
Views
6
CrossRef citations to date
0
Altmetric
Drug Evaluation

The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis

Zenas Z. N. YiuDermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UKORCID Iconhttp://orcid.org/0000-0002-1831-074XView further author information
ORCID Icon &
Richard B. WarrenDermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UKCorrespondence[email protected]
View further author information
Pages 243-249 | Received 04 Oct 2016, Accepted 16 Dec 2016, Published online: 01 Jan 2017

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jillian Frieder, Dario Kivelevitch, Connie Tran Fiore, Saadeddine Saad & Alan Menter. (2018) The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis. Expert Review of Clinical Immunology 14:1, pages 1-19.
Read now
Gaëlle Clavel, Marie-Christophe Boissier, Johanna Sigaux & Luca Semerano. (2017) Developments with experimental and investigational drugs for axial spondyloarthritis. Expert Opinion on Investigational Drugs 26:7, pages 833-842.
Read now

Articles from other publishers (4)

Diamant Thaçi, Sascha Gerdes, Kristian Gaarn Du Jardin, Jean-Luc Perrot & Lluís Puig. (2022) Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies. Dermatology and Therapy 12:10, pages 2325-2341.
Crossref
Gangadhar Hari, Anoop Kishore & Sreedhara Ranganath Pai Karkala. (2022) Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?. European Journal of Pharmacology 929, pages 175147.
Crossref
Feras M. Ghazawi, Farhan Mahmood, Leon Kircik, Yves Poulin, Marc Bourcier, Ronald Vender, Marni C. Wiseman, Charles Lynde & Ivan V. Litvinov. (2021) A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. Frontiers in Medicine 8.
Crossref
Alan Menter, Gerald G. Krueger, So Yeon Paek, Dario Kivelevitch, Iannis E. Adamopoulos & Richard G. Langley. (2021) Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. Dermatology and Therapy 11:2, pages 385-400.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.